Merck & Company Inc. (NYSE:MRK)
Bands
Volume
200 SMA
50 SMA
20 SMA
Videos
Alerts
Articles
Events
Old Forum Content for MRK
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- Pard: $MRK breakout
- BarryC: Hi everyone, GM!! I'm currently #Long: $AVCA, BVN, $CVNA, $DELL, $FCX, $GNRC, $MRK, $MU, $PTSG, $RDDT, $SMTC & $URA I also have some JUNK $GME
- BarryC: @BarryC $AVCA $BVN $CVNA $DELL $FCX $GNRC $MRK $MU $PTSG $RDDT $SMTC $URA $GME #Long I forgot to mention I am long a few this week $NVDA 1000 CALLS (Hero or zero) PURE GAMBLE
- PhilHarmonic: @BarryC $AVCA $CVNA $DELL $FCX $GNRC $MRK $MU $PTSG $RDDT $SMTC $URA $GME #Long Wishing you good luck with your basket of stocks. I like all of them.
- BarryC: @PhilHarmonic $AVCA $CVNA $DELL $FCX $GNRC $MRK $MU $PTSG $RDDT $SMTC $URA $GME #Long Ty sir... I have STOPS in place and will NOT THINK one iota, They either go UP or I get stopped. Strict Plan! :-)
- BarryC: Hi Everyone, Im currently #Long: $ACVA, $CFG, CVNA, $DELL, $FCX, $MRK, $MU, $LWL, $PSTG $RDDT & $URA. Also have some PURE JUNK $GME
- BarryC: Hi everyone, Im currently #Long: $CFG, $CVNA, $DELL, $FCX, $MRK, $MU, PTSG & $RDDT also have some (small) JUNK $GME
- BarryC: Good Morning!! Been a bit MIA, haven't been pressing much, Sorry.... I'm currently #Long: $CFG, $DELL, $FCX, $MRK, $MU, $PTSG & $RDDT I also have a little $GME pure JUNK
- joelsg1: @woodman $VKTX $PFE $MRK $JNJ $REGN $RHHBY (Roche) in the game as well with early results this am.
- Bs7518: @woodman $VKTX $PFE $MRK $JNJ $REGN Thank you for sharing its helps me stay clear on what i'm doing. You ROCK:)
-
woodman: ...
All this speculation wouldn't be complete without speculating about who would buy or partner with VKTX. Many have speculated $PFE. I don't think so because it still has to digest all that SGEN debt on the books, and there are other BPs with more ... - Geewhiz: @woodman $VKTX $PFE $MRK $JNJ $REGN Thank you for these thoughts. Holding $ARDX and $VKTX since you first mentioned. Much appreciated and much appreciate your sharing. Pardon that pun! ;-)
- woodman: @DavidK $VKTX $LLY - I think they all do to some extent. I don't know how it compares. Don't over think it. Obesity is a HUGE Total Addressable Market. $100B or more annually by 2030. Most of LLY's $760B market cap is due to its obesity/diabetes med ...
- phgruver: @woodman $LLY $ABBV, $LLY and $MRK are certainly driving $XLV higher!
- woodman: @MongosPawn $PDSB - Yesterday it announced the retirement of its current CMO and her replacement. This replacement is a heavy-weight who could have gone anywhere, including Big Pharma, but chose this little company. https://www.pdsbiotech.com/index. ...
- MongosPawn: @woodman $PDSB $MRK $BMY Great info as usual woodman. Thanks.
- woodman: @MongosPawn $PDSB $MRK $BMY - You're welcome.
- Bs7518: @woodman $PDSB $MRK $BMY Thank you sir
- phgruver: I'm not seeing much to do, today, but one thing of note: If $PFE holds yesterday's low of $28.27, this may be a good place to add in a LT account. $BMY also looks good right here for an income producing portfolio. Both of these are lagging their peers $ABBV, $GSK, $LLY & $MRK, so I expect them to play catch up.
- woodman: @wijimmy $CLRB $AMAM - Dayum! JPM kicked-off with a bunch of acquisitions by $JNJ, $NVS, $MRK. Good way to kick off 2024. Good sign for biotech.
- woodman: @woodman $CLRB $AMAM $JNJ $NVS $MRK o $HARP acquired by $MRK. Big move.
- woodman: $PDSB - I'm rebuilding a position in this one. Lots of important catalysts coming in October. Deep pipeline. It has some collaborations with $MRK (combo with Merck's Keytruda which is the SOC in those areas currently, but Merck needs to extend its patent so is in a lot of trials with other companies' cancer drug candidates). It's also working with with Mayo Clinic, MD Anderson and NIH/NCI. See pipeline here: https://www.pdsbiotech.com/index.php/pipeline/pipeline-oncology Currently trading at $6.32 (up from $4.62 Friday last week). Price targets: Cantor $25; HCW $21; Oppy $24; CG Capital $18. For some good info, see if you can get CG Capital's latest report from August. Google "CGCapital PDSB" then hit the images tab at top of your browser (if using Chrome, this works). Not sure if it will bring up this most recent report (August); it may only give you an earlier one.
- sierramp: @woodman $PDSB $MRK Thank you for sharing your research. Impressive collaborations, partner funded trials and PTs. The number of funds with ownership has been climbing, now at 82. I took a starter.
- woodman: @sierramp $PDSB $MRK - You're welcome, and good luck!
- jwstich: @woodman $PDSB $MRK. I took a very small pilot position. Thanks for your hard work and generosity.
- bud_ozborn: I am seeing movement out of tech names and into pharma and banks RED $DDOG $SPLK $ARKK $CRWD green $ABT $LLY $BMY $MRK $PFE $KEY $PACW $SCHW $GS $STNE $NU
- woodman: $PDSB - I'm still in this and have been adding (both before and after the 5/25 pre-ASCO data announcement for one of its many cancer trials). It will be presenting a fuller picture of the recent data at ASCO in the afternoon on Mon. 6/5 followed by a ...
- gtr89: @woodman $PDSB $MRK thanks for the $PDSB update. Nice move on volume today. I still have my full position and intend to keep holding, but it is tempting to take some off
- woodman: @gtr89 $PDSB $MRK - I'm sticking with mine through ASCO and following presentation/conference call. Then I'll decide what to do in terms of taking some off to use the $$ elsewhere. There are a number of biotechs I'd like to add to, but I have to sell things to do that. It's a lot of whack-a-mole and threading needles to try to rotate money around these without missing a catalyst run in one while taking advantage of dips in others. And PDSB has so much going on, it may be hard to sell without missing the next catalyst run.
- wpsimril: $MRK Nice BO; will volume hold it up?
- woodman: $TERN $VKTX $MDGL $ETNB - $MRK just bought Prometheus (immunology) before Phase 3 has started. I think there was another recent acquisition of a company with a Phase 2 drug.
- woodman: Big announcement that $MRK is acquiring $RXDX (immunology space). RXDX (up almost 80% today on this news) has no Phase 3 drug, which is kind of amazing. Shows that Big Pharma is really on the hunt for new therapies in big markets. I think it makes $VKTX even more attractive and it's coming 2Q Phase 2B data for its NASH drug (another big market) will be very important. If successful, one can reasonably believe it to be an acquisition target even though not at the Phase 3 finish line. It also has early good Phase 1 data for its obesity drug. Granted, that's far from the finish line, but it's an added something for Big Pharma if already interested in the NASH drug. It has other stuff in the pipeline as well to add spice to any thoughts by Big Pharma of scooping up VKTX for NASH. Just some food for thought.
- joelsg1: @woodman $MRK $RXDX $VKTX Nice call, and for awhile!
- woodman: @woodman $MRK $RXDX $VKTX - Thank you, and also for ignoring my stinkers. :-) Speaking of my stinkers, $XFOR rose from the dead last week. It had a nice pop on late breaking data and news that it will be presenting at the Clinical Immunology Society on 5/16 to provide an update on US regulatory activities in support of potential NDA submission for its Mavorixafor for WHIM (warts, hypagammaglobulinemia, infections, and mylokathexis). It's now flagging just under the 200d barrier.
- debeers: $MRK-morning news: Merck announces the FDA accepted application for KEYTRUDA plus chemotherapy as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma 6:46 AM ET, 04/13/2023 - Briefing.com The sBLA is based on data from the KEYNOTE-859 trial, in which KEYTRUDA plus chemotherapy demonstrated a statistically significant improvement in overall survival (OS) versus chemotherapy alone, regardless of PD-L1 expression, in patients who were human epidermal growth factor receptor 2 (HER2) negative. The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of December 16, 2023.
-
debeers: $MRK-seems like once a month or so there is a new indication for Keytruda and it is my choice for the cancer space where other less extreme drugs have failed,
Also, IMO no matter what, even if a recession comes and you are forced to delay your cruis ... - debeers: $MRK-B of A raises from neutral to buy. Recent on head and neck cancer impressive. Under a half an hour away from the Goldman Sachs conference.
- debeers: Scrapped $PYPL and $AEM Added $BKE &$SLB ( or if you are in for a day GUSH) i'm not so $SLB as oil going back up $ACHR/$ARDX/$BA/$BKE/$MRK/$SLB/$WYNN LONGS ALL
- debeers: $MRK- LONG FORM--from the conference Keytruda and Guardacil expand their uses and ease of administering. There is no other cancer vaccine at the current time. They are also involved in animal health and immunology. Acceleron acquisition endpoints keep being moved out and he paticept.Acceleron phase 3 team fully supported and Merck has made these acquisitions before and are recruiting faster than before. LVL biomarker research is something that they believe can be delivered in an oral drug. Considering that an elevated LVL has a direct relationship to cardio disease and death- this critical research and development. They are continuing to monitor antivirals as relatrd to Covid and other viruses. SHORT FORM: Expectation that phase 3 trials will succeed with FDA high. Merck has very few misses.LONG
-
debeers: $MRK- So here's what the IBD had to say: much more eloquently than i did while listening to the healthcare conference call:
LONG FORM;In the span of a month in late 2022, Merck (MRK) gained a new chief executive, announced a $1.35 billion takeover a ... - debeers: $BA-how many airlines are there.2. $CF-just a bit $MRK-makes its numbers and does its own due dil so i don't have to police it $SCHW-early because it won't go up really until the 2nd half. i have to go to the analyst meeting and then i wll hear what the brokers are asking $SLB & $VLO are we replacing reserves? NO. Are we recognizing that energy is, along with food, a necessary commodity and a refiner and a servicer is where i want to be $TMUS-Delta gave TMUS a present today. It announced free wi-fi for its customers in flight and its the only carrier AND they didn't even put it to bid! Yowza! Instant revenue increase for $TMUS
- scottrades: My notes: $SPY Awaiting more Data $QQQ Awaiting Apple’s Breakdown $DIA Tap Dancing on the trendline $XLE Back in the range $GDX Holding up $KWEB Holding the gap $XHB Dan added some stocks to the ATL $XBI Tight $AAPL Not a good look. $MSFT The future? $BABA Strength in some China Stocks. $PDD Breaking out $KRYS Dan mentioned this one $CPRX I own this $ACLX Trying to move out of a base $LABU For those who like to live dangerously $MRK Breaking out $FCX Copper trying to move $WPM Still own this. $NEM Holding up. $GOLD 200 Day Support $XOM Sling Shot? Watch 110 $CROX Mentioned in the forum $CELH at the 50 Day $PLNT It is January $SBUX Clear resistance $BOX Nope.
- debeers: LONGS ALL- $BA- since 140, $NEM will do way better than GDXJ imo, $NKE, sneaking upward, $PYPL, $WYNN er winner chicken dinner. Will add $MRK back--big mistake to have removed it. I gave the reason yesterday why i prefer picking a stock to an etf.
- debeers: $MRK -back in 111.56. Why? 3 upgrades BEFORE THE GOLDMAN SACHS CONFERENCE TOMORROW. you might get it for a few pennies less but here's the why of the buy: 1. Baird upgrade 2.$MRK-Immutep achieves 50% enrollment milestone in randomised phase IIb TACTI-003 trial for first line head & neck cancer 6:24 AM ET, 01/04/2023 - Briefing.com Co announces that it has enrolled and randomised over 50% of the planned 154 patients in the TACTI-003 Phase IIb trial. TACTI-003 is evaluating Immutep's first-in-class soluble LAG-3 protein eftilagimod alpha ("efti"), in combination with MSD's (MRK) anti-PD-1 therapy KEYTRUDA (pembrolizumab) as 1st line treatment of recurrent or metastatic head and neck squamous cell carcinoma (1L HNSCC). 3. GS has always had $MRK as a top pick
- jpoko13: @debeers $MRK bought a starter...I like your synopsis
- woodman: $LVS breakout - Besides LVS, I'm in very little other than a number of select biotech stocks. My non-biotech is LVS $NFLX (bought this morning) $ELF $GDXJ, and big pharma $MRK and $LLY
- jonwest88: @woodman @champ $LVS $NFLX $ELF $GDXJ $MRK $LLY Ulta Beauty $ULTA since 11/15 approx., this one has returned about the same as $ELF.
- woodman: @jonwest88 $LVS $NFLX $ELF $GDXJ $MRK $LLY $ULTA - I love the consolidation in $ELF after a monster 170+ % run from May 2022 (vs Ulta 45%). ELF is taking a well deserved and encouraging rest as it consolidates into the rising 50d which has almost caught up. I think ELF is preparing for another move higher soon. Maybe not this week, but soon. I continue to hold it. I have to check my notes but I think I bought it back in August. (Maybe earlier, I can't recall.)
- jonwest88: @woodman $LVS $NFLX $ELF $GDXJ $MRK $LLY $ULTA HAVE put $ELF on the watch, as I have had a small bit of $ULTA since 9/1 and mid Oct. Lucked out with Cramer rave fave $EL. Nice run on that one from below $200 a few months ago
- woodman: @jonwest88 $LVS $NFLX $ELF $GDXJ $MRK $LLY $ULTA $EL - Excellent work with $EL! Congrats.
- debeers: $MRK-2 pieces of good news: 1. china grants conditional emergency approval for Merck's Covid treatment- . china grants emergency approval for Molnupiravir This is for use in adults with risk of Covid progressing to severe from moderate. The bodies piling up outside the crematories is not a good look. In my view, there should be 3 waves of the disease: Coastal which should recover first as that is where Covid struck first, 2nd the high population cities and 3rd inland country. In the meantime of course, the Chinese are anxious to travel and spread what they refused for so long to control to everyone else.
- steve71: @debeers $MRK Good info, thanks.
- woodman: @debeers $MRK - MRK has a patent cliff in 2028 for its all-star cancer med Keytruda. So, it's machine gun firing around the cancer sphere to find combinations with small biotech drugs/therapies to "extend" the patent. I see so many of these smaller biotechs with their therapies in combo trials with Keytruda. I think there will be gold in some of these combinations.
- debeers: $MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, is scheduled to participate in a fireside chat at the Goldman Sachs Healthcare CEOs Unscripted Conference on Thursday, Jan. 5, 2023, at 8:55 a.m. ET. IMO you might want to listen to this one. More for the Questions and comments from Goldman than even what Merck says. Pulled back a few cents because it has run so much. IMO the best is yet to be.
-
Rockstar: ...
The market had the $IWM, and the $DIA, but those indices have been struggling over the last three weeks. This last week is a week to be careful. Still no oversize positions and this is still a traders market, not a swing market. I am still looking a ... - debeers: From the WSJ- In deciding today between choosing a healthcare provider or pharmas, i decided on the pharmas after a really long article in the journal about how healthcare companies are findiong that fewer hospitals are locating in the poorer areas. Drug companies are in the driver seat, therefore, in my opinion. LONG THE MERKSTER$MRK who has lotsa fingers in lotsa cancer pies pies and my spec $ARDX/
- debeers: $COP/$MRK/$SCHW/$TS-relative strength so far above the others compelled to buy $ARDX-down due to index, not research. Still way above the 20 day but had to sell it. Fell below VWAP.
- Justhanging48: @debeers $COP $MRK $SCHW $TS $ARDX Taking a starter on $TS. Thank you for posting your actions.
-
Rockstar: ...
The $XLV bounced off the 50 day EMA yesterday and while it is pushing against the 21 EMA today this is another sector that could be bullish going into the end of the year. $LLY,$MRK, $CI, and $UNH are stocks to review for opportunities in the $XLV ... - debeers: AND THEN THERE WERE 5 $ARDX (prem amt same as $BA/$MRK/$NKE/$SCHW)-all premium amounts the same
- debeers: @SCOTTRADES-why is $NKE showing down here? the stock is UP as is $ARDX/$MRK/
- woodman: @debeers $ARDX $BA $MRK $NKE $SCHW - Though I'm thinking that $ARDX gets back to about $4-$5 on a favorable FDA decision in a few weeks, note that the gap from CRL back in July 2001 goes to $7.35. So, some good/great potential here.
- debeers: @woodman $ARDX $BA $MRK $NKE $SCHW -no value judgment just reporting. Likei said, if it gets to 5.25 and wants to go higher---who am i to stop it?
- debeers: $ARDX/$LEN/$MRK/$NKE-i'll buy back $TECK if it can climb a bit first. i figure maybe a buck or so. Altogether, considering the $BA squish, not a bad day. Now no more $BA and no more $TECK until they fly right and harden up. others Long
- Mounty: @debeers $ARDX $LEN $MRK $NKE $TECK $BA What do you see as the $LEN driver with increasing interest rates?
- debeers: @DAN- i know this is selfish of me but it will be my birthday soon and what i would like is for you to do is go on vacay for another week . i have absolutely no idea why this is because no matter what the averages show on the screen, i do really well when you are away so all i am asking is, if you are having a good time could you take just a couple of more days off??? Thanks so much. debeers $ARDX/$LEN/$MRK and $TECK if it goes up another buck or so is when i want to buy it back
- debeers: @Mounty $ARDX $LEN $MRK $NKE $TECK $BA -IMO and its just me, $LEN has a really nice balance sheet.They are tremendous stewards of cash. i also think that a certain person from Omaha has been sniffing around them.just sayin'
- debeers: $LEN@Mounty-here's what i see.@Mounty $ARDX $LEN $MRK $NKE $TECK -IMO and its just me, $LEN has a really nice balance sheet.They are tremendous stewards of cash. i also think that a certain person from Omaha has been sniffing around them.just sayin'
- debeers: $MRK-New drug approved for patients with Metastatic Castration resistant prostste cancer.
- Henry: @debeers $MRK Jeez, this has to be the first post I see. Ouch..😒 Good news for the patients that have condition because there isn't much else for them.
- debeers: @Henry $MRK -If i made you reach protectively for your nether regions, sorry H! Desperate times, desperate measures.
- debeers: $ARDX/$BA/$MRK/$NKE/$SCHW-new/$TECK-LONG
- woodman: Current #biotech and Big #Pharma that I'm in: $ARDX (gift drop 2 days ago; catalyst with news likely in January - see my prior posts) $CPRX (keeps going) $ORMP (strong today; catalyst into January for P3 results for oral insulin; also, CEO just talke ...
-
debeers: ...
3. $MRK-Gets priority review from FDA for urothelial cancer
4A&B --T
$HAL/$SLB there are things i like about $HAL/$SLB-i think both will outperform the others in energy over the next 12 months
5.. $SMCI-Addded to the S&P midcap index
6. $ST ... - debeers: $AVGO/$BA/$BOX/$HSY/$MRK/$HSY/$LLY/$MRK/$MSFT/$TXRH-LONGS all.
- woodman: $MRK trying to break-out of a some consolidation. Not sure it's quite ready though. But keep on radar. I do have a position in this already.
- woodman: @Justhanging48 $MRNA - news on its melanoma combo therapy with $MRK. Very early stage, however. Could speed along quickly, though.
- Justhanging48: @woodman $MRNA $MRK Wouldn't chase this as I have seen this situation so many times before. Stocks pops on the story, then fades since it is in a very early stage.
- woodman: @Justhanging48 $MRNA $MRK - no doubt.
- debeers: The message for all companies on earnings is that the risk cannot simply beat. Must beat and raise. ideally crush and raise. With that in mind: $CELH/$DXCM/$HSY/$MRK/$STLD/$URI- we already discussed that, with money tight and loans for equipment being more expensive :RENT IT-LONGS ALL
- issues: @debeers $CELH $DXCM $HSY $MRK $STLD $URI We have all those positions except $DXCM. We compared DXCM to $PODD but didn't buy either.
- debeers: $CPB/$HSY/$ENPH/$LOW/$M/$MRK/$ULTA- long
-
Rockstar: ...
The $DIA and $IWM continue their strength with some strength in more than a couple ETF's. The ETF's that I am looking at long positions include $TAN, $XLF, $XLE, $XLB, $XLI, $XLP, $XLV, $XME,and $IYT. Of these, I am hesitant on the $XLE with oi ... -
Rockstar: ...
Specific stocks I am looking at for longs are in the health care sector with $JNJ,$ABBV,$VRTX,$MRK,$CI and $UNH on that list. I am also looking at $PEP $COST,$WMT, $TMUS (already long), $NUE $GS and $AXP for longs in the $XLV and $XLF sectors. ... -
Rockstar: ...
So what do we do now. I was long the semis ($ON and $NVDA) on Monday, as mentioned in my missive on that day, and sold my positions on Tuesday. In hindsight it would have been a nice hold through yesterday's numbers, but I did not want to hold ... - jwstich: @Rockstar and @DAN $SPY $DIA $QQQ $IWM $ON $NVDA $SMH $XLV $AMGN $MRK $VRTX $MCK $XLE $CVX $XOM $DVN $OXY $XLF $GS $MET $AFL Do you still plan on combining SMM and OMM in some fashion? If so, when might this happen? I would be very much interested at looking at the combination. BTW, nice note this am Rocky.
- DAN: @jwstich $SPY $DIA $QQQ $IWM $ON $NVDA $SMH $XLV $AMGN $MRK $VRTX $MCK $XLE $CVX $XOM $DVN $OXY $XLF $GS $MET $AFL We are just working on the pricing now. I'm hoping that we can even get it done in time for Black Friday...and if not, then early December. It's a priority...there are just some complexities that are under the hood. Sorry for the delay.
-
Rockstar: ...
I am looking at the $DIA and $IWM for longs. The sectors are $XLB,$XLE,$XLF,$XLV and I am eyeing the $SMH as well. I know that has more to do with the $QQQ's but that sector has shown some strength recently. The stocks I am looking at within thes ... - debeers: $MRK-Profit up 20% on Keytruda success. No disappointments here. None.
- debeers: $MTDR- Raymond James just upped their outlook to 78. The only 1 international that i still have that is down--as i had to give up on $TSLA and $LRCX due to China shennanigans is $MAR and staying with that because of superior earnings history and the stronger dollar has been amazing for travelers to Europe. Otherwise: $MOH reporting 10/26 AMC-NO MISSES $MTDR 10/25 AMC $PPG, $SLB already reported fantastic, $STLD beat whereas someone else's $NUE did not--just saying. When there's not a lot to do, i try to do nothing. Staying away from most consumer discretionary for now and its killin' me. But i know very few folks who are making major expenses now. $MRK-breaking out imo.
- scottrades: Some #Earnings to be aware of this week: $AAPL $AMZN $MSFT $META $GOOGL $UPS $SHOP $GM $KO $BA $CLF $F $PHG $XOM $HAL $INTC $GE $VLO $MMM $ENPH $V $JBLU $CVX $CMG $BOH $RTX $AJG $DORM $MCD $CAT $WM $LUV $MA $SHW $PINS $SCHN $BMY $MRK $BIIB $ADM $X $SPOT $KEX $KHC $DX
- Justhanging48: $MRK seems to be headed to 100 with the Vol and price move if it can get thru resistance this 3rd time
- mopick: @Justhanging48 $MRK, sold mine with a small profit. Triple top looming, see how it does tomorrow.
- issues: IBD not working due to maintenance but here are the IBD 50 for this week: $CCRN $MTDR $VRTX $WWE $PXD $SRPT $CIVI $EOG $COP $TALO $NOG $HRMY $FANG $SM $PERI $CVI $DVN $DECK $AMN $MOH $AHCO $DAR $MRK $HAE $EBC $HUM $MRO $LW $OXY $AMR $TTC $WAFD $NBIX $HES $APA $VNOM $PDCE $ERF $HCC $SLVM $PCAR $ONB $CORT $GMAB $CVBF $TNK $PNFP $CADE $GBCI $UCBI
- Maxtrade: @dan Is $MRK a break out?
- champ: $ENPH....@ $253....this turn could continue, Day-Trade......other boring positions that I'm working.....$OC $CMC $LLY $AZO $FREY $XPER $HNST $AXON $PENN.... .......also Watching $PLL $MRK $GUSH $GBTC and #others..... because the guess is....the markets might turn, at some point...... so for Now....the daily zig-zags are on going....however just about everything seems to be spring-loaded, for a bounce...... and if it happens.... I'm Ready and Waiting. $QQQ....if the tech sector turns, stocks in that sector will have the largest bounce.....and I have a Watch Lists. However for now.....everything is all screwed-up.
- sgiseller: $MRK $LLY $ABBV starting very small positions in all
-
Rockstar: ...
Tech health care and semis is where I will look to see if taking a few bullish trades are right for me. I will pay particular attention to the FANGS and some health care such as $MRK and $UNH. There are some potential shorts as well such as $CSCO, $ ... - bigbartabs: @Rockstar $HYG $VIX $DXY $MRK $UNH $CSCO $DIS $DE $SPY ... what indicator leads you to the $SPX 3840 level (which I agree with). The 6/13 week high? Keep up your morning thoughts Rocky... all the best.
-
scottrades: ...
I pointed out a few setups that I’m watching last night. Really interested in the Drug Manufacturers right now, like $MRK and $LLY. Also want to see some more strength in the $SMH Stocks like $AMD $ON $NVDA $MU and the like.
As Rocky and I ...
| Stock Price | $99.18 |
| Change | -0.68% |
| Volume | 14,029,700 |
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.
Request Video of MRKAlready a member? Sign in here.
Past Month
Leading Peers
-
$22.94 120.28%
-
$26.04 59.03%
-
$372.26 20.10%
Past Month
Lagging Peers
-
$14.20 -169.73%
-
$12.60 -22.57%
-
$42.90 -21.22%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!